Trial
NCT04024384
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
Phase IIWITHDRAWNSAFETYConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
Multiple Myeloma
Intervention
Daratumumab
Why stopped
Promotor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-27